NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $3.16 +0.11 (+3.43%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Embecta Stock (NASDAQ:EMBC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Embecta alerts:Sign Up Key Stats Today's Range$2.98▼$3.1850-Day Range$2.90▼$9.7852-Week Range$2.77▼$15.55Volume777,337 shsAverage Volume1.38 million shsMarket Capitalization$187.78 millionP/E Ratio1.67Dividend Yield18.96%Price Target$11.00Consensus RatingStrong Sell Company Overview Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes. The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices. These products are designed to support patients across the spectrum of diabetes management, from intensive insulin therapy to routine self-testing and continuous glucose monitoring systems. Embecta serves customers in more than 100 countries through a network of direct and indirect distribution channels that include hospitals, clinics, retail pharmacies and e-commerce platforms. The company maintains a global footprint with manufacturing and distribution sites strategically located across North America, Europe and the Asia-Pacific region to ensure supply continuity and responsiveness to regional regulatory requirements. Embecta is led by President and Chief Executive Officer Anthony J. Parker, whose leadership team leverages deep expertise in medical technology to drive innovation and expand the company’s product pipeline. Going forward, Embecta aims to enhance patient outcomes by advancing next-generation insulin delivery systems and digital health integrations that support personalized diabetes management. AI Generated. May Contain Errors. Read More Embecta Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreEMBC MarketRank™: Embecta scored higher than 83% of companies evaluated by MarketBeat, and ranked 68th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingStrong Sell Consensus RatingEmbecta has received a consensus rating of Strong Sell. The company's average rating score is 1.40, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 3 sell ratings.Upside PotentialEmbecta has a consensus price target of $11.00, representing about 247.6% upside from its current price of $3.17.Amount of Analyst CoverageEmbecta has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Embecta's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.02% Earnings GrowthEarnings for Embecta are expected to grow by 8.02% in the coming year, from $1.62 to $1.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 1.66, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.52.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 1.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.81.Read more about Embecta's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.33% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 8.52.Change versus previous monthShort interest in Embecta has recently increased by 4.29%, indicating that investor sentiment is decreasing. Dividend3.3 / 5Dividend StrengthStrong Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 20.69%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 31.58%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 34.29% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. News and Social Media2.5 / 5News Sentiment0.05 News SentimentEmbecta has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Embecta this week, compared to 2 articles on an average week.Search Interest22 people have searched for EMBC on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have not sold or bought any company stock.Percentage Held by Insiders1.30% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EMBC Stock News HeadlinesEmbecta Corp. (EMBC) Securities Fraud Investigation - Levi & KorsinskyMay 20 at 9:00 AM | prnewswire.comEmbecta (NASDAQ:EMBC) Price Target Lowered to $3.00 at Bank of AmericaMay 19 at 3:25 AM | americanbankingnews.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 21 at 1:00 AM | Brownstone Research (Ad)Embecta (EMBC) price target decreased by 24.00% to 12.92May 16, 2026 | msn.comEmbecta faces US reset as CEO bets on GLP-1, Owen Mumford diversificationMay 16, 2026 | msn.comembecta Completes Acquisition of Owen Mumford Holdings LimitedMay 15, 2026 | globenewswire.comEmbecta (EMBC) Stock Forecast & Price TargetMay 14, 2026 | investing.comWhy Embecta's (NASDAQ:EMBC) Earnings Are Better Than They SeemMay 14, 2026 | finance.yahoo.comSee More Headlines EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $11.88 on January 1st, 2026. Since then, EMBC shares have decreased by 73.4% and is now trading at $3.1650. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) announced its quarterly earnings data on Tuesday, May, 5th. The company reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by $0.15. Embecta's revenue was down 14.4% on a year-over-year basis. Read the conference call transcript. Who are Embecta's major shareholders? Top institutional shareholders of Embecta include SG Americas Securities LLC (1.75%), Dimensional Fund Advisors LP (1.58%), Bank of New York Mellon Corp (1.39%) and Walleye Capital LLC (1.34%). Insiders that own company stock include Devdatt Kurdikar, David F Melcher, Jacob Elguicze, Jeffrey Z Mann and Milton Mayo Morris. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Embecta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Record date for 3/17 Dividend2/27/2026Ex-Dividend for 3/17 Dividend2/27/2026Dividend Payable3/17/2026Last Earnings5/05/2026Today5/21/2026Record date for 6/15 Dividend5/28/2026Ex-Dividend for 6/15 Dividend5/28/2026Dividend Payable6/15/2026Next Earnings (Estimated)8/06/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 EMBC's financial health is in the Red zone, according to TradeSmith. EMBC has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryMedical Equipment Current SymbolNASDAQ:EMBC CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees1,850Year Founded2022Price Target and Rating Average Price Target for Embecta$11.00 High Price Target$25.00 Low Price Target$3.00 Potential Upside/Downside+247.6%Consensus RatingStrong Sell Rating Score (0-4)1.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$1.90 Trailing P/E Ratio1.67 Forward P/E Ratio1.95 P/E GrowthN/ANet Income$95.40 million Net Margins10.73% Pretax Margin16.27% Return on Equity-23.96% Return on Assets14.12% Debt Debt-to-Equity RatioN/A Current Ratio2.46 Quick Ratio1.68 Sales & Book Value Annual Sales$1.08 billion Price / Sales0.17 Cash Flow$4.40 per share Price / Cash Flow0.72 Book Value($10.55) per share Price / Book-0.30Miscellaneous Outstanding Shares59,330,000Free Float58,557,000Market Cap$187.78 million OptionableOptionable Beta1.09 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:EMBC) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
